



Prothena Corporation plc  
Investor Relations Department  
331 Oyster Point Blvd  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

NASDAQ: PRTA	
Last Trade:	45.85
Trade Time:	4:00 PM ET Nov 22, 2017
Change:	-0.12  (-0.261%)
Day Range	45.27 - 46.45
52-Week Range	44.43 - 70.00
Volume	336,314

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Nov 22, 2017 [Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Nov 16, 2017 [Prothena Highlights Breadth of Novel Pipeline at R&D Day](#)
- Nov 7, 2017 [Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update](#)
- Nov 1, 2017 [Prothena to Participate in the Credit Suisse 26th Annual Healthcare Conference](#)
- Oct 31, 2017 [Prothena to Report Third Quarter 2017 Financial Results on November 7](#)

## Upcoming Events [\[ View all \]](#)

- Nov 30, 2017 1:15 PM ET [Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 27, 2017 [Annual Report \(10-K\)](#)
- Mar 31, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 9, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)